Evidence map›Paper›PMID 23245769›Full record

ArticleEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology2013

Influence of a latrophilin 3 (LPHN3) risk haplotype on event-related potential measures of cognitive response control in attention-deficit hyperactivity disorder (ADHD).

Andreas J Fallgatter, Ann-Christine Ehlis, Thomas Dresler, Andreas Reif, Christian P Jacob, Mauricio Arcos-Burgos, Maximilian Muenke, Klaus-Peter Lesch

Abstract read
In one paragraph

Article in European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Novel non-stimulants rescue hyperactive phenotype in an adgrl3.1 mutant zebrafish model of ADHD.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Article
  7. Article
  8. Article
  9. Driver mutations in ADGRL3 are involved in the evolution of ependymoma.Laboratory investigation; a journal of technical methods and pathology · 2022
    Article
  10. Latrophilin-3 disruption: Effects on brain and behavior.Neuroscience and biobehavioral reviews · 2021
    Review
  11. Brain sciences · 2021
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Genetic Approaches to Understanding Psychiatric Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Andreas J FallgatterDepartment of Psychiatry and Psychotherapy, University of Tuebingen, Germany. Andreas.Fallgatter@med.uni-tuebingen.de
Ann-Christine Ehlis
Thomas Dresler
Andreas Reif
Christian P Jacob
Mauricio Arcos-Burgos
Maximilian Muenke
Klaus-Peter Lesch
Universitätsklinikum Würzburg · DEAustralian National University · AUUniversity of Tübingen · DE

Funding

Genetic Analysis of Attention Deficit Hyperactivity DisorderZIAHG000175 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI SHAW, PHILIP · 2009 to 2025
$13.4M
Intramural NIH HHS ZIA HG000175
6 · The paper itself

Abstract

Current research strategies have made great efforts to further elucidate the complex genetic architecture of attention-deficit hyperactivity disorder (ADHD). The present study examined the impact of an LPHN3 haplotype that has recently been associated with ADHD (Arcos-Burgos et al., 2010) on neural activity in a visual Go-NoGo task. Two hundred sixteen adult ADHD patients completed a Continuous Performance Test (CPT) while the ongoing EEG was simultaneously recorded. Results showed that patients carrying two copies of the LPHN3 risk haplotype (n=114) made more omission errors and had a more anterior Go-centroid of the P300 than patients carrying at least one LPHN3 non-risk haplotype (n=102). Accordingly, the NoGo-Anteriorization (NGA; topographical ERP difference of the Go- and NoGo-condition), a neurophysiological marker of prefrontal functioning, was reduced in the LPHN3 high risk group. However, in the NoGo-condition itself no marked differences attributable to the LPHN3 haplotype could be found. Our findings indicate that, within a sample of ADHD patients, the LPHN3 gene impacts behavioral and neurophysiological measures of cognitive response control. The results of our study further strengthen the concept of an LPHN3 risk haplotype for ADHD and support the usefulness of the endophenotype approach in psychiatric and psychological research.

Indexed as

Polymorphism, Single NucleotideAdultAttention Deficit Disorder with HyperactivityBehaviorBiomarkersCognition DisordersDiagnostic and Statistical Manual of Mental DisordersElectroencephalographyEvoked PotentialsFemaleGenetic Association StudiesGermanyHumansMaleNerve Tissue ProteinsNeuronsADGRL3 protein, humanBiomarkersNerve Tissue ProteinsReceptors, G-Protein-CoupledReceptors, Peptide

Identifiers

PMID23245769
PMCPMC4131948
OpenAlexW2025095843

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.